Upstream Bio vs Xenetic Biosciences
Upstream Bio and Xenetic Biosciences are similar in size: $2.9m and $3.0m of revenue in their latest fiscal years. Upstream Bio grew faster (20.4% against 19.0%). Xenetic Biosciences kept more of each dollar of sales as profit: a net margin of -90.1% against -5026.0%.
| Latest fiscal year | Upstream BioUPB, 2025 | Xenetic BiosciencesXBIO, 2025 |
|---|---|---|
| Revenue | $2.9m | $3.0m |
| Revenue growth | 20.4% | 19.0% |
| Net income | −$143m | −$2.7m |
| Operating margin | -5618.8% | — |
| Net margin | -5026.0% | -90.1% |
| Return on equity | -35.4% | -40.0% |
| Free cash flow | −$133m | −$2.3m |
| Cash | $102m | $7.9m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 75 | — |
| Market value | $182m | $5.0m |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 15 sales | 0 buys, 0 sales |